Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline Characteristics by Baseline N-BNP Level

Published byRidwan Budiono Modified over 5 years ago

Similar presentations

Presentation on theme: "Baseline Characteristics by Baseline N-BNP Level"— Presentation transcript:

1 Baseline Characteristics by Baseline N-BNP Level
Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

2 Risk of Major Vascular Events, Stroke, Major Coronary Events, and Heart Failure Hospitalization or Death, by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

3 Relative Hazard of Vascular Events and Hospitalization or Death Due to HF by Baseline N-BNP Level (Adjusted for Differences in Baseline Characteristics) Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

4 Effects of Simvastatin on Vascular Events in Participants Subdivided by Baseline N-BNP Level
Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

5 Absolute Benefits of Simvastatin Allocation on
First MVE and First MCE, by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

6 Effects of Simvastatin on Vascular and Nonvascular Mortality in Participants Subdivided by Baseline N-BNP Level Heart Protection Study Collaborative Group. J Am Coll Cardiol 2007;49:311-9

Download ppt "Baseline Characteristics by Baseline N-BNP Level"

Similar presentations

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):1943-1950.

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Lancet 2005 366: 1267-1134 doi:10.1016/S0140-6736(08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.

PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,

Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:645-54.

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.

ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:1267-78.

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Causal Assessment of Serum Urate Levels in Cardiometabolic.

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Causal Assessment of Serum Urate Levels in Cardiometabolic.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Similar presentations

Ads by Google